Its business is the marketing of veterinary pharmaceutical products.
Véto-pharma develops and makes available to French beekeepers one of the first Asian hornet traps. Today, this trap is recognized as the most effective one on the market.
After more than 4 years of development and a large investment, Véto-pharma obtains authorization to market Apivar in the United States, thus opening the doors to one of the largest beekeeping markets in the world.
This strategic decision is based on the firm convictions of the management team regarding the importance and necessity of creating a global expert in bee health. As a result, we reinvented our way of doing business, and strengthened our ambition to succeed.
Refocusing the company on international growth and innovative apiculture products required that we abandon non-apiculture-related activities that, in 2010, represented more than 50% of our revenue. This fact alone demonstrates our deep commitment to apiculture.
Acquisition of Apiten in Japan. Apiten is a medication used in treatment against foulbrood, and a leader in the Japanese market.
Introduction of Apivar in Afghanistan.
Introduction of Apivar in Albania and Lebanon: The Véto-pharma range is now distributed in more than 20 countries worldwide.
Launch of the NutriBee Propolis nutritional product range.
Installation of a testing apiary with 150 colonies dedicated to Research and Development activities.
Construction of eva (Espace de Valorisation de l’Abeille, or Honey Bee Valuation Center) begins.
The “Espace de Valorisation de l’Abeille”, or Honey Bee Valuation Center.